MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
News headline image
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
From Pfizer Inc.
Via Business Wire
Tickers PFE ROIV
News headline image
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Third-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
News headline image
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story